Histologically confirmed diagnosis of adenocarcinoma of the rectum
Histologically or cytologically confirmed prostate cancer
Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum
Participants must have histologically or cytologically confirmed adenocarcinoma of the rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically- or cytologically-confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ
Histologically confirmed adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Histologically or cytologically confirmed PSCC
Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
Patients must have histologically or cytologically confirmed metastatic or unresectable adenocarcinoma of the colon or rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate and the availability archival prostate tumor sample is required
Participants with histologically or cytologically confirmed diagnosis of adenocarcinoma of the GEJ or stomach will be enrolled in this study
Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum that is metastatic or unresectable.
Histologically and cytologically documented diagnosis as gastroesophageal adenocarcinoma.
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of prostate.
Histologically or cytologically confirmed prostate carcinoma.
Has histologically or cytologically documented adenocarcinoma NSCLC.
Histologically or cytologically confirmed adenocarcinoma of the prostate.
Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
Subjects must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic disease
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
New diagnosis of histologically confirmed adenocarcinoma of the rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate (the availability archival prostate tumor sample is preferred not required)
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed
Histologically or cytologically confirmed adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
Histologically or cytologically confirmed adenocarcinoma of the prostate
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically confirmed metastatic adenocarcinoma of the lung
Histologically or cytologically confirmed prostate adenocarcinoma
Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
Histologically confirmed adenocarcinoma of the rectum
Histologically or cytologically proven adenocarcinoma of the colon or rectum
The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+
The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma
Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed carcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate
Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum.
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate at either MSKCC or at the participating site
I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.
Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
Histologically or cytologically confirmed prostate cancer
Histologically or cytologically confirmed adenocarcinoma of the prostate.
Histologically or cytologically confirmed adenocarcinoma consistent clinically with androgen independent prostate cancer
Histologically or cytologically proven adenocarcinoma of the breast
Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.
Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
Histologically or cytologically proven adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the breast.
Patient must have histologically or cytologically confirmed colorectal adenocarcinoma or small bowel adenocarcinoma
Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuous medical castration (for >=8 weeks prior to Screening)
Histologically or cytologically confirmed adenocarcinoma of the prostate;
The participant has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC.
Histologically or cytologically confirmed adenocarcinoma of the prostate;
Have a histologically or cytologically-confirmed diagnosis of adenocarcinoma of the GEJ or stomach
Histologically or cytologically confirmed unresectable or metastatic esophagogastric adenocarcinoma
Histological or cytologically confirmed prostate adenocarcinoma
Has histologically or cytologically documented adenocarcinoma NSCLC
